Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 4/20 | 0.68 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.68 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.68 |
| ▸ | CDK2 | P24941 | 3/20 | 0.68 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.68 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.68 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.68 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.54 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | PRKACA | P17612 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13952907 | 0.87 | CDK2 (0.72) | CDK9CDK5CDK5R1CDK2CCNT1 | |
| SCHEMBL13175163 | 0.86 | CDK9 (0.71) | CDK9CDK5CDK5R1CDK2CCNT1 | |
| SCHEMBL13175363 | 0.84 | CDK9 (0.68) | CDK9CDK5CDK5R1CDK2CCNT1 | |
| Variolin B SCHEMBL13175404 | 0.84 | CDK2 (0.68) | CDK9CDK5CDK5R1CDK2CCNT1 | |
| Variolin B SCHEMBL29353680 | 0.84 | CDK2 (0.68) | CDK9CDK5CDK5R1CDK2CCNT1 | |
| SCHEMBL13202875 | 0.84 | CDK9 (0.61) | CDK9CDK5CDK5R1CDK2CCNT1 | |
| SCHEMBL13175411 | 0.84 | CDK9 (0.53) | CDK9CDK5CDK5R1CDK2CCNT1 | |
| SCHEMBL13202992 | 0.82 | CDK9 (0.51) | CDK9CDK5CDK5R1CDK2CCNT1 | |
| SCHEMBL13202991 | 0.82 | CDK9 (0.51) | CDK9CDK5CDK5R1CDK2CCNT1 | |
| SCHEMBL13202876 | 0.81 | CDK9 (1.00) | CDK9CDK5CDK5R1CDK2CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1867645-B1 | Variolin derivatives and their use as antitumor agents | PHARMA MAR SA (ES) | 2010-09-08 | — | — | EP | disclosed |
| US-7772241-B2 | Variolin derivatives and their use as antitumor agents | PHARMA MAR S.A. (ES) | 2010-08-10 | — | — | US | disclosed |
| US-7772241-B2 | Variolin derivatives and their use as antitumor agents | PHARMA MAR S.A. (ES) | 2010-08-10 | — | — | US | disclosed |
| US-20090197901-A1 | VARIOLIN DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | PHARMA MAR, S.A. (ES) | 2009-08-06 | — | — | US | disclosed |
| US-20090197901-A1 | VARIOLIN DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | PHARMA MAR, S.A. (ES) | 2009-08-06 | — | — | US | disclosed |
| US-7495000-B2 | Variolin derivatives and their use as antitumor agents | PHARMA MAR, S.A. (ES) | 2009-02-24 | — | — | US | disclosed |
| US-7495000-B2 | Variolin derivatives and their use as antitumor agents | PHARMA MAR, S.A. (ES) | 2009-02-24 | — | — | US | disclosed |
| EP-1404668-B1 | VARIOLIN DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | PHARMA MAR SA (ES) | 2008-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197901-A1 | VARIOLIN DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | CBR3, CCNL2, HRH3 | CDK9 1364/4885CDK5 580/4885CDK5R1 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.